These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 28952473)
1. [Pitavastatin and new diabetes development]. Beyaz Ş; Ükinç K Turk Kardiyol Dern Ars; 2017 Apr; 45(Suppl 3):13-15. PubMed ID: 28952473 [TBL] [Abstract][Full Text] [Related]
2. [Statins diabetogenicity: are all the same? state of art]. Rius Tarruella J; Millán Núñez-Cortés J; Pedro-Botet J; Pintó Sala X Clin Investig Arterioscler; 2015; 27(3):148-58. PubMed ID: 25835612 [TBL] [Abstract][Full Text] [Related]
4. A Multi-Center, Open-Label, Two-Arm Parallel Group Non-inferiority Randomized Controlled Trial Evaluating the Effect of Pitavastatin, Compared to Atorvastatin, on Glucose Metabolism in Prediabetics with Hypertension and Dyslipidemia: Rationale and Design for the China Hemoglobin A1c Metabolism Protection Union Study (CAMPUS). Zhang J; Shao Y; Liu Y; Tao J Cardiovasc Drugs Ther; 2018 Dec; 32(6):581-589. PubMed ID: 30187345 [TBL] [Abstract][Full Text] [Related]
5. Could changes in adiponectin drive the effect of statins on the risk of new-onset diabetes? The case of pitavastatin. Arnaboldi L; Corsini A Atheroscler Suppl; 2015 Jan; 16():1-27. PubMed ID: 25575403 [TBL] [Abstract][Full Text] [Related]
6. Pitavastatin - from clinical trials to clinical practice. Masana L Atheroscler Suppl; 2010 Dec; 11(3):15-22. PubMed ID: 21193154 [TBL] [Abstract][Full Text] [Related]
7. Statin diabetogenicity: guidance for clinicians. Ray K Cardiovasc Diabetol; 2013; 12 Suppl 1(Suppl 1):S3. PubMed ID: 23819776 [TBL] [Abstract][Full Text] [Related]
8. Are all statins the same? Focus on the efficacy and tolerability of pitavastatin. da Silva PM Am J Cardiovasc Drugs; 2011; 11(2):93-107. PubMed ID: 21446776 [TBL] [Abstract][Full Text] [Related]
14. Long-term Effects of high-doSe pitavaStatin on Diabetogenicity in comparison with atorvastatin in patients with Metabolic syndrome (LESS-DM): study protocol for a randomized controlled trial. Park JB; Jung JH; Yoon YE; Kim HL; Lee SP; Kim HK; Kim YJ; Cho GY; Sohn DW Trials; 2017 Oct; 18(1):501. PubMed ID: 29078817 [TBL] [Abstract][Full Text] [Related]
15. Searching the place of pitavastatin in the current treatment of patients with dyslipidemia. Barrios V; Escobar C; Zamorano JL Expert Rev Cardiovasc Ther; 2013 Dec; 11(12):1597-612. PubMed ID: 24215190 [TBL] [Abstract][Full Text] [Related]
16. Pitavastatin and carbohydrate metabolism: what is the evidence? Filippatos TD; Elisaf MS Expert Rev Clin Pharmacol; 2016 Jul; 9(7):955-60. PubMed ID: 26967972 [TBL] [Abstract][Full Text] [Related]
17. Incidence of new-onset diabetes with 1 mg versus 4 mg pitavastatin in patients at high risk of developing diabetes during a 3-year follow-up. Jeong HS; Hong SJ; Son S; An H; Kook H; Joo HJ; Park JH; Yu CW; Lim DS Cardiovasc Diabetol; 2019 Nov; 18(1):162. PubMed ID: 31752850 [TBL] [Abstract][Full Text] [Related]
18. Statin-induced myotoxicity: pharmacokinetic differences among statins and the risk of rhabdomyolysis, with particular reference to pitavastatin. Catapano AL Curr Vasc Pharmacol; 2012 Mar; 10(2):257-67. PubMed ID: 22022768 [TBL] [Abstract][Full Text] [Related]
19. The role of fenofibrate in clinical practice. Zambon A; Cusi K Diab Vasc Dis Res; 2007 Sep; 4 Suppl 3():S15-20. PubMed ID: 17935056 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of pitavastatin, a new HMG-CoA reductase inhibitor, on lipid and glucose metabolism in patients with type 2 diabetes. Kawai T; Tokui M; Funae O; Meguro S; Yamada S; Tabata M; Shimada A Diabetes Care; 2005 Dec; 28(12):2980-1. PubMed ID: 16306567 [No Abstract] [Full Text] [Related] [Next] [New Search]